Imago BioSciences Management
Management criteria checks 2/4
Imago BioSciences' CEO is Hugh Rienhoff, appointed in Mar 2012, has a tenure of 10.83 years. total yearly compensation is $6.40M, comprised of 7.5% salary and 92.5% bonuses, including company stock and options. directly owns 1.48% of the company’s shares, worth $18.07M. The average tenure of the management team and the board of directors is 1.1 years and 3.3 years respectively.
Key information
Hugh Rienhoff
Chief executive officer
US$6.4m
Total compensation
| CEO salary percentage | 7.5% |
| CEO tenure | 10.8yrs |
| CEO ownership | 1.5% |
| Management average tenure | 1.1yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Imago BioSciences (NASDAQ:IMGO) Is In A Good Position To Deliver On Growth Plans
Nov 08
Imago BioSciences GAAP EPS of -$0.41 beats by $0.09
Aug 12Here's Why We're Not Too Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Situation
Jul 26Companies Like Imago BioSciences (NASDAQ:IMGO) Are In A Position To Invest In Growth
Apr 12We're Not Very Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Rate
Dec 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$62m |
| Jun 30 2022 | n/a | n/a | -US$57m |
| Mar 31 2022 | n/a | n/a | -US$52m |
| Dec 31 2021 | US$6m | US$481k | -US$42m |
| Sep 30 2021 | n/a | n/a | -US$33m |
| Jun 30 2021 | n/a | n/a | -US$26m |
| Mar 31 2021 | n/a | n/a | -US$21m |
| Dec 31 2020 | US$733k | US$418k | -US$18m |
Compensation vs Market: Hugh's total compensation ($USD6.40M) is about average for companies of similar size in the US market ($USD5.11M).
Compensation vs Earnings: Hugh's compensation has increased whilst the company is unprofitable.
CEO
Hugh Rienhoff (69 yo)
10.8yrs
Tenure
US$6,397,318
Compensation
Dr. Hugh Young Rienhoff, Jr., M.D., serves as Chairman of the Board at Parvus Therapeutics Inc. since July 16, 2019. Dr. Rienhoff serves as a Managing Director of Life Science Venture Partners. He serves a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 10.8yrs | US$6.40m | 1.48% $ 18.1m | |
| Chief Financial Officer | 1.3yrs | US$1.91m | 0.73% $ 8.9m | |
| Chief Operating & Business Officer | less than a year | no data | 0.15% $ 1.9m | |
| Senior VP of Finance & Principal Accounting Officer | less than a year | no data | 0.078% $ 955.6k | |
| Chief of Technical Operations | less than a year | US$428.49k | 0.42% $ 5.1m | |
| Global Head of Clinical Operations | 10.8yrs | US$423.39k | 0.44% $ 5.4m |
1.1yrs
Average Tenure
52yo
Average Age
Experienced Management: IMGO's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 10.8yrs | US$6.40m | 1.48% $ 18.1m | |
| Independent Chairman of the Board | 8.3yrs | US$38.80k | 0.077% $ 939.6k | |
| Independent Director | 1.2yrs | US$322.05k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$246.71k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$247.41k | 0.0025% $ 30.7k | |
| Independent Director | 1.9yrs | US$559.65k | 0% $ 0 |
3.3yrs
Average Tenure
62.5yo
Average Age
Experienced Board: IMGO's board of directors are considered experienced (3.3 years average tenure).